You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CARNITOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Carnitor, and when can generic versions of Carnitor launch?

Carnitor is a drug marketed by Leadiant Biosci Inc and is included in three NDAs.

The generic ingredient in CARNITOR is levocarnitine. There are four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Carnitor

A generic version of CARNITOR was approved as levocarnitine by HIKMA on March 29th, 2001.

  Try a Trial

Drug patent expirations by year for CARNITOR
Drug Prices for CARNITOR

See drug prices for CARNITOR

Recent Clinical Trials for CARNITOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Oncology GroupPhase 3
M.D. Anderson Cancer CenterPhase 2
National Cancer Institute (NCI)Phase 2

See all CARNITOR clinical trials

Pharmacology for CARNITOR
Drug ClassCarnitine Analog

US Patents and Regulatory Information for CARNITOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Leadiant Biosci Inc CARNITOR levocarnitine TABLET;ORAL 018948-001 Dec 27, 1985 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Leadiant Biosci Inc CARNITOR levocarnitine SOLUTION;ORAL 018948-002 Apr 27, 1988 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CARNITOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CARNITOR

See the table below for patents covering CARNITOR around the world.

Country Patent Number Title Estimated Expiration
Australia 3050201 ⤷  Try a Trial
European Patent Office 1257266 ⤷  Try a Trial
Canada 2381187 CARNITINE PAR INTRAVEINEUSE DESTINEE AU TRAITEMENT DE PATIENTS SOUFFRANT D'UREMIE CHRONIQUE SOUMIS A UNE DIALYSE PERIODIQUE (INTRAVENOUS CARNITINE FOR THE TREATMENT OF CHRONIC URAEMIC PATIENTS UNDERGOING PERIODICAL DIALYSIS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.